<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03091673</url>
  </required_header>
  <id_info>
    <org_study_id>XSGP-302</org_study_id>
    <nct_id>NCT03091673</nct_id>
  </id_info>
  <brief_title>Glucose Response of G-Pen (Glucagon Injection) in Pediatric T1D Patients</brief_title>
  <official_title>A Phase 3 Study to Evaluate the Glucose Response of G-Pen (Glucagon Injection) in Pediatric Patients With Type 1 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xeris Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Emmes Company, LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Xeris Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a sequential efficacy and safety study in pediatric patients with type 1 diabetes.
      Subjects will be administered insulin to induce a low normal glycemic state and will then
      receive an age-appropriate dose of G-Pen (glucagon injection) in a clinical research center
      (CRC) or comparable setting.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label, Phase 3 sequential efficacy and safety study in pediatric patients
      ages 2-17 with type 1 diabetes. Patients will complete the screening procedures up to 30 days
      before dosing to determine eligibility before enrollment to the treatment phase.

      The procedure to evaluate the efficacy of G-Pen (glucagon injection) consists of inducing a
      low normal glycemic state by administration of insulin. Subjects ages 2-11 will then be given
      a 0.5 mg dose of G-Pen, while subjects ages 12-17 will receive a 1 mg dose of G-Pen. Subjects
      ages 12-17 will return for a second visit 1-4 weeks later and will receive a 0.5 mg dose of
      G-Pen when in a low normal glycemic stare. Plasma glucose and glucagon levels will be
      monitored for 90 and 180 minutes post-dosing, respectively, at all visits.

      A follow-up phone call as a safety check will be conducted 3 - 14 days following
      administration of the final dose.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 27, 2017</start_date>
  <completion_date type="Actual">September 27, 2017</completion_date>
  <primary_completion_date type="Actual">September 7, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Plasma Glucose</measure>
    <time_frame>0-30 minutes</time_frame>
    <description>The primary endpoint for this study is an evaluation of change in plasma glucose following treatment with G-Pen, with an emphasis on the increase from baseline to 30 minutes post-dosing.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time for Plasma Glucose to Increase by ≥25 mg/dL</measure>
    <time_frame>0-90 minutes</time_frame>
    <description>Time for plasma glucose to increase by ≥25 mg/dL from baseline will be analyzed descriptively for each age cohort.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Glucagon Area Under the Curve</measure>
    <time_frame>0-90 minutes</time_frame>
    <description>Plasma glucagon area under the curve (AUC) for each age cohort will be analyzed descriptively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Glucagon Cmax</measure>
    <time_frame>0-180 minutes</time_frame>
    <description>Plasma glucagon maximum concentration for each age cohort will be analyzed descriptively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Glucagon Tmax</measure>
    <time_frame>0-180 minutes</time_frame>
    <description>Plasma glucagon time to maximum concentration for each age cohort will be analyzed descriptively.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Diabetes Mellitus, Type 1</condition>
  <arm_group>
    <arm_group_label>G-Pen (glucagon injection) 0.5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single 0.5 mg subcutaneous (SC) injection of G-Pen (glucagon injection)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>G-Pen (glucagon injection) 1.0 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single 1.0 mg subcutaneous (SC) injection of G-Pen (glucagon injection)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glucagon</intervention_name>
    <description>0.5 or 1.0 mg of pre-mixed liquid Xeris glucagon delivered via auto-injector</description>
    <arm_group_label>G-Pen (glucagon injection) 0.5 mg</arm_group_label>
    <arm_group_label>G-Pen (glucagon injection) 1.0 mg</arm_group_label>
    <other_name>G-Pen (glucagon injection)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  diagnosed with T1D for at least 6 months at Screening.

          -  current usage of daily insulin treatment.

        Exclusion Criteria:

          -  pregnant or nursing

          -  renal insufficiency

          -  hepatic synthetic insufficiency

          -  aspartate or alanine aminotransferase &gt; 3 times the upper limit of normal

          -  hematocrit less than or equal to 30%

          -  use of &gt; 2.0 U/kg total insulin dose per day

          -  inadequate venous access

          -  current seizure disorder

          -  history of pheochromocytoma or disorder with increased risk of pheochromocytoma

          -  history of insulinoma

          -  history of glycogen storage disease.

          -  active use of alcohol or drugs of abuse

          -  administration of glucagon within 14 days of the first treatment visit

          -  participation in other studies involving an investigational drug or device within 30
             days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barbara Davis Center for Childhood Diabetes</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale University</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52422</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Women &amp; Children's Hospital of Buffalo</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14222</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>March 16, 2017</study_first_submitted>
  <study_first_submitted_qc>March 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 27, 2017</study_first_posted>
  <results_first_submitted>October 17, 2018</results_first_submitted>
  <results_first_submitted_qc>October 17, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">November 16, 2018</results_first_posted>
  <last_update_submitted>November 16, 2018</last_update_submitted>
  <last_update_submitted_qc>November 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glucagon</mesh_term>
    <mesh_term>Glucagon-Like Peptide 1</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>December 6, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/73/NCT03091673/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 16, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/73/NCT03091673/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>G-Pen (Glucagon Injection) 0.5 mg</title>
          <description>A single 0.5 mg subcutaneous (SC) injection of G-Pen (glucagon injection)
Glucagon: 0.5 or 1.0 mg of pre-mixed liquid Xeris glucagon delivered via auto-injector</description>
        </group>
        <group group_id="P2">
          <title>G-Pen (Glucagon Injection) 1.0 mg</title>
          <description>A single 1.0 mg subcutaneous (SC) injection of G-Pen (glucagon injection)
Glucagon: 0.5 or 1.0 mg of pre-mixed liquid Xeris glucagon delivered via auto-injector</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Dose</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="0">All 31 subjects received the 0.5 mg dose during period 1.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Second Dose</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0">No subjects received the 0.5 mg dose during period 2.</participants>
                <participants group_id="P2" count="11">Only the 11 study subjects ages 12-&lt;18 years were assigned the 1 mg dose during period 2.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Subjects 2 to &lt;6 Years of Age</title>
          <description>Study subjects at least 2, but less than 6 years of age at the time of dosing</description>
        </group>
        <group group_id="B2">
          <title>Subjects 6 to &lt;12 Years of Age</title>
          <description>Study subjects at least 6, but less than 12 years of age at the time of dosing</description>
        </group>
        <group group_id="B3">
          <title>Subjects 12 to &lt;18 Years of Age</title>
          <description>Study subjects at least 12, but less than 18 years of age at the time of dosing</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
            <count group_id="B2" value="13"/>
            <count group_id="B3" value="11"/>
            <count group_id="B4" value="31"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.96" spread="1.1"/>
                    <measurement group_id="B2" value="9.95" spread="2.25"/>
                    <measurement group_id="B3" value="15.48" spread="1.58"/>
                    <measurement group_id="B4" value="10.79" spread="4.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="31"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Plasma Glucose</title>
        <description>The primary endpoint for this study is an evaluation of change in plasma glucose following treatment with G-Pen, with an emphasis on the increase from baseline to 30 minutes post-dosing.</description>
        <time_frame>0-30 minutes</time_frame>
        <population>All enrolled subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>Subjects 2 to &lt;6 Years of Age</title>
            <description>Study subjects at least 2, but less than 6 years of age at the time of receiving a 0.5 mg dose of G-Pen.</description>
          </group>
          <group group_id="O2">
            <title>Subjects 6 to &lt;12 Years of Age</title>
            <description>Study subjects at least 6, but less than 12 years of age at the time of receiving a 0.5 mg dose of G-Pen.</description>
          </group>
          <group group_id="O3">
            <title>Subjects 12 to &lt;18 Years of Age</title>
            <description>Study subjects at least 12, but less than 18 years of age at the time of receiving a 1 mg dose of G-Pen.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Plasma Glucose</title>
          <description>The primary endpoint for this study is an evaluation of change in plasma glucose following treatment with G-Pen, with an emphasis on the increase from baseline to 30 minutes post-dosing.</description>
          <population>All enrolled subjects.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.4" spread="18.3"/>
                    <measurement group_id="O2" value="84.2" spread="25.3"/>
                    <measurement group_id="O3" value="54.0" spread="27.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value was computed using a t-test to determine if change in plasma glucose from baseline to 30 minutes was zero.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time for Plasma Glucose to Increase by ≥25 mg/dL</title>
        <description>Time for plasma glucose to increase by ≥25 mg/dL from baseline will be analyzed descriptively for each age cohort.</description>
        <time_frame>0-90 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Subjects 2 to &lt;6 Years of Age</title>
            <description>Study subjects at least 2, but less than 6 years of age at the time of receiving a 0.5 mg dose of G-Pen.</description>
          </group>
          <group group_id="O2">
            <title>Subjects 6 to &lt;12 Years of Age</title>
            <description>Study subjects at least 6, but less than 12 years of age at the time of receiving a 0.5 mg dose of G-Pen.</description>
          </group>
          <group group_id="O3">
            <title>Subjects 12 to &lt;18 Years of Age</title>
            <description>Study subjects at least 12, but less than 18 years of age at the time of receiving a 1 mg dose of G-Pen.</description>
          </group>
        </group_list>
        <measure>
          <title>Time for Plasma Glucose to Increase by ≥25 mg/dL</title>
          <description>Time for plasma glucose to increase by ≥25 mg/dL from baseline will be analyzed descriptively for each age cohort.</description>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.4" spread="3.78"/>
                    <measurement group_id="O2" value="16.2" spread="4.63"/>
                    <measurement group_id="O3" value="26.6" spread="9.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Glucagon Area Under the Curve</title>
        <description>Plasma glucagon area under the curve (AUC) for each age cohort will be analyzed descriptively.</description>
        <time_frame>0-90 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Subjects 2 to &lt;6 Years of Age</title>
            <description>Study subjects at least 2, but less than 6 years of age at the time of receiving a 0.5 mg dose of G-Pen</description>
          </group>
          <group group_id="O2">
            <title>Subjects 6 to &lt;12 Years of Age</title>
            <description>Study subjects at least 6, but less than 12 years of age at the time of receiving a 0.5 mg dose of G-Pen</description>
          </group>
          <group group_id="O3">
            <title>Subjects 12 to &lt;18 Years of Age</title>
            <description>Study subjects at least 12, but less than 18 years of age at the time of receiving a 1 mg dose of G-Pen</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Glucagon Area Under the Curve</title>
          <description>Plasma glucagon area under the curve (AUC) for each age cohort will be analyzed descriptively.</description>
          <units>min*mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14440.8" spread="2114.9"/>
                    <measurement group_id="O2" value="14392.3" spread="2698.4"/>
                    <measurement group_id="O3" value="13105.5" spread="13105.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Glucagon Cmax</title>
        <description>Plasma glucagon maximum concentration for each age cohort will be analyzed descriptively.</description>
        <time_frame>0-180 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Subjects 2 to &lt;6 Years of Age</title>
            <description>Study subjects at least 2, but less than 6 years of age at the time of receiving a 0.5 mg dose of G-Pen.</description>
          </group>
          <group group_id="O2">
            <title>Subjects 6 to &lt;12 Years of Age</title>
            <description>Study subjects at least 6, but less than 12 years of age at the time of receiving a 0.5 mg dose of G-Pen.</description>
          </group>
          <group group_id="O3">
            <title>Subjects 12 to &lt;18 Years of Age</title>
            <description>Study subjects at least 12, but less than 18 years of age at the time of receiving a 1 mg dose of G-Pen.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Glucagon Cmax</title>
          <description>Plasma glucagon maximum concentration for each age cohort will be analyzed descriptively.</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="202.3" spread="35.9"/>
                    <measurement group_id="O2" value="216.3" spread="51.2"/>
                    <measurement group_id="O3" value="199.0" spread="57.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Glucagon Tmax</title>
        <description>Plasma glucagon time to maximum concentration for each age cohort will be analyzed descriptively.</description>
        <time_frame>0-180 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Subjects 2 to &lt;6 Years of Age</title>
            <description>Study subjects at least 2, but less than 6 years of age at the time of receiving a 0.5 mg dose of G-Pen.</description>
          </group>
          <group group_id="O2">
            <title>Subjects 6 to &lt;12 Years of Age</title>
            <description>Study subjects at least 6, but less than 12 years of age at the time of receiving a 0.5 mg dose of G-Pen.</description>
          </group>
          <group group_id="O3">
            <title>Subjects 12 to &lt;18 Years of Age</title>
            <description>Study subjects at least 12, but less than 18 years of age at the time of receiving a 1 mg dose of G-Pen.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Glucagon Tmax</title>
          <description>Plasma glucagon time to maximum concentration for each age cohort will be analyzed descriptively.</description>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.6" spread="10.5"/>
                    <measurement group_id="O2" value="68.5" spread="15.3"/>
                    <measurement group_id="O3" value="81.2" spread="14.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected from the signing of informed consent through the follow-up phone call, which was completed 3-14 days after the last dose of treatment. The maximum adverse event (AE) collection period was 44 days for subjects receiving a single dose, and 72 days for subjects receiving 2 doses of G-Pen.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Subjects 2 to &lt;6 Years of Age</title>
          <description>Study subjects at least 2, but less than 6 years of age at the time of receiving a 0.5 mg dose of G-Pen.</description>
        </group>
        <group group_id="E2">
          <title>Subjects 6 to &lt;12 Years of Age</title>
          <description>Study subjects at least 6, but less than 12 years of age at the time of receiving a 0.5 mg dose of G-Pen.</description>
        </group>
        <group group_id="E3">
          <title>Subjects 12 to &lt;18 Years of Age</title>
          <description>Study subjects at least 12, but less than 18 years of age at the time of receiving a 1 mg dose of G-Pen.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA 20.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="13"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="13"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="13"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Martin J. Cummins, VP, Clinical Development</name_or_title>
      <organization>Xeris Pharmaceuticals, Inc.</organization>
      <phone>806-282-2120</phone>
      <email>mcummins@xerispharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

